ÂÜÀòÂÒÂ×

Abby Pulsipher has over 9 years of experience in the discovery and preclinical development of glycosaminoglycan-based candidate drugs for oncology and respiratory diseases. She secured $4.5M in SBIR awards (NIAID/NIH), oversees GlycoMira’s chronic rhinosinusitis drug program, and is an inventor on multiple patents. Dr. Pulsipher operates cross-functionally to manage and unify team input across industries while considering resource efficiency to achieve milestones. She is Director of Basic and Translational Rhinology Research and a Core Member of the Utah Center for Nanomedicine at the University of Utah. Prior to receiving a doctorate degree in chemistry at UNC-Chapel Hill and completing a postdoctoral fellowship (HHMI) in chemical glycobiology at CalTech, Dr. Pulsipher aided the discovery of novel candidate drugs at Adenosine Therapeutics, which was acquired by Clinical Data (now Allergan) to clinically advance stedivaze as a cardiac stress agent for diagnosing coronary artery disease.